FDA Clearance Tracker · K260770
LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteX
Last checked: Nov 19, 2026Latest source record: Jun 4, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Jun 4, 2026
Substantially Equivalent
Time to decision
87 days
Received Mar 9, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K260770
- Device name
- LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteX
- Applicant
- DiaSorin, Inc.
- Applicant location
- Stillwater, MN
- Received
- Mar 9, 2026
- Decided
- Jun 4, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 866.3172
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code LOM. The earliest in FDA's data is P780016-S002, decided Mar 17, 1980.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K260770
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for DiaSorin, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
P250039 · Decided May 7, 2026 · 220 days after receipt
Device type: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGM (MYM) · Laboratory Medicine & Pathology
- LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261)New device typeBreakthroughDe Novo
DEN250032 · Decided Dec 23, 2025 · 146 days after receipt
Device type: Device To Detect Antibodies To Hepatitis D Virus (SGW) · Laboratory Medicine & Pathology
P220034 · Decided Mar 29, 2024 · 458 days after receipt
Device type: ASSAY,ENZYME LINKED IMMUNOSORBENT,PARVOVIRUS B19 IGG (MYL) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.